AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company", today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7,519,351 shares of common stock, par value $0.001 per share (the "Common Stock") (or common stock equivalents in lieu thereof) at a purchase price of $0.325 per share. The gross proceeds to the Company from the offering are expected to be approximately $2.4 million, before deducting placement agent commissions and other offering expenses. In addition, in a concurrent private placement, the Company will issue and sell unregistered Series I warrants (the "Series I Warrants") to purchase up to 15,038,702 shares of Common Stock. The Series I Warrants will have an exercise price of $0.325 per share, will be exercisable subject to stockholder approval and will expire five (5) years from the initial exercise date.

The offering is expected to close on or about May 21, 2026, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the offering for (i) the manufacture of clinical drug supply, (ii) the Company's planned Phase 3 clinical trial activities, and (iii) working capital purposes.